Genmab A/S (LTS:0MGB)
kr 1839.5 -9.25 (-0.5%) Market Cap: 117.16 Bil Enterprise Value: 88.58 Bil PE Ratio: 22.31 PB Ratio: 3.70 GF Score: 88/100

Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 07:00PM GMT
Release Date Price: kr1958.5 (-0.55%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Great. Good afternoon, everyone. Welcome to the 3 p.m. session of day 3 at the Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and U.S. biopharma for the firm.

I've got the great pleasure of hosting Genmab today in our fireside chat. With us is Anthony Pagano. He is Executive Vice President and Chief Financial Officer for the company. It's a role that he had -- recently appointed to him.

And with that, Anthony, I want to welcome you to your first GS Global Healthcare Conference. Hopefully, next year, we can do this in person in Southern California.

Anthony Pagano;S;Executive VP;CFO
Genmab A

/-&

Yes, Graig. It's an absolute pleasure to be here and look forward to sort of talking about all the exciting stuff that's going on here at Genmab. And I can honestly say, there's really been never more exciting time for the company, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot